|
Total number of studies included
|
96
| |
| | |
Original articles
|
82
|
85.4
|
| | |
Abstracts
|
14
|
14.6
|
|
Year of publication
|
| | |
2009
|
6
|
6.3
|
| | |
2010
|
7
|
7.3
|
| | |
2011
|
8
|
8.3
|
| | |
2012
|
12
|
12.5
|
| | |
2013
|
17
|
17.7
|
| | |
2014
|
29
|
30.2
|
| | |
2015
|
17
|
17.7
|
|
Global distribution of location of institutions of selected studies
|
| | |
North America
|
54
|
56.3
|
| | |
Europe
|
21
|
21.9
|
| | |
Asia
|
18
|
18.7
|
| | |
Australia/Africa/South America (1 each)
|
3
|
3.1
|
|
Single vs multi-institutional
|
| | |
Single institution
|
83
|
86.5
|
| | |
Multi-institutional
|
13
|
13.5
|
|
Type of study
|
| | |
Retrospective series
|
54
|
56.3
|
| | |
Phase 2 studies
|
22
|
22.9
|
| | |
Prospective series
|
11
|
11.5
|
| | |
Phase 1 studies
|
5
|
5.2
|
| | |
Phase 1/2 studies
|
3
|
3.1
|
| | |
Phase 3 studies
|
1
|
1
|
|
Criteria for resectability
|
| | |
NCCN/AHPBA/SSO/SSAT consensus
|
38
|
39.6
|
| | |
MD Anderson
|
8
|
8.3
|
| | |
Other
|
29
|
30.2
|
| | |
Not mentioned
|
21
|
21.9
|
|
Number of studies of each local/anatomical stage
|
| | |
Resectable
|
18
|
18.8
|
| | |
Borderline resectable (BR)
|
15
|
15.6
|
| | |
Locally advanced unresectable (LA)
|
29
|
30.2
|
| | |
R + BR
|
5
|
5.2
|
| | |
BR + LA
|
24
|
25
|
| | |
R + BR + LA
|
5
|
5.2
|
|
Number of patients in each anatomical stage
|
| | |
Resectable
|
1056
|
19.1
|
| | |
Borderline resectable (BR)
|
935
|
16.9
|
| | |
Locally advanced unresectable (LA)
|
1840
|
33.3
|
| | |
R + BR
|
202
|
3.7
|
| | |
BR + LA
|
1014
|
18.4
|
| | |
R + BR + LA
|
473
|
8.6
|
|
Criteria for of radiology response assessment
|
| | |
RECIST
|
48
|
50
|
| | |
WHO
|
5
|
5.2
|
| | |
Other
|
2
|
2.1
|
| | |
Not mentioned
|
41
|
42.7
|
|
Criteria for toxicity assessment
|
| | |
NCI CTCAE
|
43
|
44.8
|
| | |
WHO
|
5
|
5.2
|
| | |
RTOG
|
2
|
2.1
|
| | |
Not mentioned/not applicable
|
46
|
47.9
|
|
Type of neoadjuvant therapy
|
| | |
Chemoradiotherapy
|
33
|
34.4
|
| | |
Chemotherapy alone
|
20
|
20.8
|
| | |
Chemotherapy with chemoradiation
|
41
|
42.7
|
| | |
Radiation alone
|
2
|
2.1
|
|
Chemotherapy drugs
|
| | |
Monotherapy (Gem/5FU/Cape/UFT/Cis)
|
26
|
27.1
|
| | |
FOLFIRINOX
|
20
|
20.8
|
| | |
Gemcitabine + oxaliplatin*
|
8
|
8.3
|
| | |
Gemcitabine or 5FU + cisplatin
|
7
|
7.3
|
| | |
Gemcitabine + Docetaxel
|
3
|
3.1
|
| | |
GTX (gemcitabine, taxane, capecitabine)
|
6
|
6.3
|
| | |
Gem + biologic (bevacizumab, cetuximab)
|
3
|
3.1
|
| | |
Gem + S1
|
5
|
5.2
|
| | |
Gem + Nab-paclitaxel
|
2
|
2.1
|
| | |
5FU + cisplatin + interferon
|
1
|
1
|
| | |
Multiple
|
11
|
11.5
|
| | |
Not mentioned
|
2
|
2.1
|
| |
None
|
2
|
2.1
|
|
Radiotherapy
|
| | |
Yes
|
76
|
79.2
|
| | |
No
|
20
|
20.8
|
